Ernexa Therapeutics Inc. Common Stock (ERNA) Stock Price

ERNAStock

$4.57−86.75%52W

Market Cap$5.33M

P/E—

PEG Ratio—

Div yield—

Beta2.62

ERNA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-51.00%

Price vs S&P 500 (4W)30.92%

VGM Score21.97

Book Value / Share (Quarterly)$5.88

P/TBV (Annual)0.78x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-69.14%

Cash Flow / Share (Quarterly)$-6.22

Price vs S&P 500 (YTD)-97.59%

Gross Margin (TTM)83.51%

Net Profit Margin (TTM)-7720.96%

EPS (TTM)$-25.77

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-25.77

Revenue Growth (5Y)-51.31%

EPS (Annual)$-55.83

Dividend / Share (Annual)$0.00

ROI (Annual)-446.97%

Gross Margin (Annual)83.51%

Net Profit Margin (5Y Avg)-7921.03%

Cash / Share (Quarterly)$7.87

ROA (Last FY)-241.41%

Revenue Growth TTM (YoY)-99.83%

EBITD / Share (TTM)$-7.67

ROE (5Y Avg)-971.78%

Operating Margin (TTM)-6600.34%

Cash Flow / Share (Annual)$-22.45

P/B Ratio1.02x

P/B Ratio (Quarterly)0.85x

Net Income / Employee (Annual)$-2,816,800

EV / Revenue (TTM)-3.28x

Net Interest Coverage (TTM)-5.41x

ROA (TTM)-228.54%

EPS Incl Extra (Annual)$-55.83

Current Ratio (Annual)1.01x

Quick Ratio (Quarterly)2.68x

3-Month Avg Trading Volume1.45M

52-Week Price Return-86.75%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.36

P/S Ratio (Annual)12.06x

Asset Turnover (Annual)0.11x

52-Week High$71.50

Operating Margin (5Y Avg)-7549.30%

EPS Excl Extra (Annual)$-55.83

CapEx CAGR (5Y)-32.80%

Tangible BV CAGR (5Y)26.77%

26-Week Price Return-39.07%

Quick Ratio (Annual)0.88x

13-Week Price Return-60.81%

Total Debt / Equity (Annual)0.31x

Current Ratio (Quarterly)2.89x

Enterprise Value$-1.91M

Revenue / Share Growth (5Y)-71.73%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-51.48%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)21.45x

Pretax Margin (Annual)-7647.59%

Cash / Share (Annual)$6.00

3-Month Return Std Dev117.83%

Gross Margin (5Y Avg)2.78%

Net Income / Employee (TTM)$-2,816,600

ROE (Last FY)-586.59%

Net Interest Coverage (Annual)-5.47x

EPS Basic Excl Extra (Annual)$-55.83

P/FCF (TTM)4.25x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.04x

EPS Incl Extra (TTM)$-25.77

Receivables Turnover (Annual)0.00x

ROI (TTM)-158.02%

P/S Ratio (TTM)12.06x

Pretax Margin (5Y Avg)-7920.90%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.36

Price vs S&P 500 (52W)-105.31%

Year-to-Date Return-84.77%

5-Day Price Return-9.24%

EPS Normalized (Annual)$-55.83

ROA (5Y Avg)-325.96%

Net Profit Margin (Annual)-7652.75%

Month-to-Date Return39.33%

Cash Flow / Share (TTM)$-4.09

EBITD / Share (Annual)$-33.65

Operating Margin (Annual)-6548.80%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-784.25%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-25.77

P/TBV (Quarterly)0.78x

P/B Ratio (Annual)3.92x

Dividend / Share (TTM)$0.00

Inventory Turnover (TTM)33.29x

Pretax Margin (TTM)-7718.38%

Book Value / Share (Annual)$7.64

Price vs S&P 500 (13W)-62.76%

Dividend Yield (TTM)0.28%

Beta2.62x

P/FCF (Annual)4.25x

Revenue / Share (TTM)$0.00

ROE (TTM)-169.40%

52-Week Low$3.18

vGradeC

gGradeF

mGradeF

vgmGradeD

ERNA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$3.30	-$3.40	-3.03%(-$0.10)
Q1 2026	May 11, 2026	-$1.95	-$6.95	-256.41%(-$5.00)

ERNA Analyst Recommendations

Mar 2023

Jun 2026

Jul 2026

Aug 2026

2.17

4.14

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ERNAErnexa Therapeutics Inc. Common Stock	C	F	F	$4.57
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Ernexa Therapeutics Inc. Common Stock

Ernexa Therapeutics is a biotechnology company developing cell-engineered medicines for cancer and autoimmune diseases. The company's proprietary platform converts induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) to create off-the-shelf cellular therapies, eliminating the need for patient-specific cell harvesting. This approach offers potential advantages in manufacturing scalability and cost-efficiency.